Green Thumb Industries: The GAAP Turnaround Masks A Worse Operating Story

Green Thumb Industries reported its first-ever GAAP quarterly profit in Q2 2026. Revenue climbed 4.6% to $306.7 million, net income hit $4.9 million versus a loss a year ago, and the stock trades around $6.89 after bouncing off a 52-week low near $4.80. Several writers have seized on the turnaround to declare the stock priced too low.

I must admit that the headline numbers look convincing until you look past them. The GAAP profit improvement is almost entirely a tax accounting event, not an operating one. And the operating picture has actually deteriorated in ways that matter more for the long-term thesis.

The Tax Tailwind That Isn't An Operating Tailwind

Here's what happened: the Department of Justice reclassified medical cannabis to Schedule III effective April 28, 2026, partially relieving Green Thumb of IRS Code Section 280E — the tax rule that prevents cannabis companies from deducting normal business expenses. Income tax expense fell from $21.6 million in Q2 2025 to $12.5 million in Q2 2026. That's a $9.1 million improvement in tax drag.

That accounting benefit is real, and it's load-bearing for the GAAP headline. Without it, the $4.9 million net income shrinks considerably. But the relief only applies to the medical portion of the business. The recreational markets — where the growth is supposed to come from — still face full 280E treatment. So the tax tailwind is partial, and its long-term significance depends on whether the recreational side ever gets the same relief.

The Operating Story Is Worse

Now strip the tax story away and look at the business itself. Green Thumb's gross margin fell from 49.9% in Q2 2025 to 45.0% in Q2 2026. That's a nearly five-percentage-point compression in a single year. Gross profit actually declined from $146.3 million to $137.9 million, even as revenue grew. The company attributed the margin erosion to price compression and brand licensing fees associated with its RYTHM portfolio.

Price compression is the industry-wide problem that no one wants to talk about. Massachusetts, New Jersey, and Pennsylvania — three of Green Thumb's largest states — are suffering from oversupply and retail competition. The company's own data shows comparable retail sales (stores open 12+ months) fell 1.1% year-over-year. That's the second consecutive quarter of negative same-store performance after a 0.5% decline in Q1.

Meanwhile, SG&A expenses climbed from $106.8 million (36.4% of revenue) to $117.9 million (38.4% of revenue). Management cited increased compensation costs for retention. So revenue grew 4.6%, gross profit shrank, and operating expenses accelerated. The result: operating income fell from $39.4 million to $20.0 million — down roughly 50%.

Normalized EBITDA — Green Thumb's preferred cash-earnings proxy, which adds back the licensing fees, stock-based compensation, and other non-operating items — came in at $84.3 million, or 27.5% of revenue, compared to $82.7 million (28.2%) a year earlier. Essentially flat. On $13.4 million more revenue, Green Thumb generated roughly the same normalized operating cash earnings.

Full-year 2025 tells a similar story. Revenue grew 3.4% to $1.2 billion, but gross margins fell from 52.9% to 48.9%, and normalized EBITDA declined from $371.3 million to $348.4 million. The margin compression trend didn't start in Q2. It's been working against Green Thumb for more than a year.

The Peer Check Doesn't Help

The competitive moat argument is where Green Thumb usually earns its premium. The company maintains number-one market share in Illinois, Pennsylvania, Ohio, Maryland, and Minnesota. It has a strong balance sheet — $283.6 million in cash against $283 million in debt at quarter end — and has been aggressively buying back shares, repurchasing approximately 29.5 million shares for $203.4 million since September 2023. That share reduction has been arguably the most shareholder-friendly move in the sector.

But the peer comparison raises questions about whether Green Thumb's margin compression is structural or competitive. Curaleaf, Green Thumb's closest U.S. rival, reported Q2 2026 revenue of $340 million with a gross margin of 50% and adjusted EBITDA of $70 million. Curaleaf's gross margin didn't collapse the way Green Thumb's did. On a revenue base 11% larger, Curaleaf maintained margins closer to where Green Thumb was a year ago.

That doesn't mean Curaleaf is winning the margin war. But it does suggest that Green Thumb's five-point gross margin decline isn't purely an industry phenomenon. Something specific to Green Thumb's cost structure, licensing obligations, or product mix is contributing to the compression.

The Guidance Is Flat

Management's own forecast adds caution to the setup. For Q3 2026, Green Thumb expects sequential revenue to be flat. The company is not guiding for growth into the next quarter. After launching adult-use sales in Minnesota in September 2025 and opening new dispensaries in New Jersey and Pennsylvania, the near-term growth engine appears to have stalled.

The bright spots — Virginia adult-use authorization beginning July 2027, a conditional license in Texas, hemp policy shifts in Ohio — are real but distant. Virginia won't produce revenue for nearly a year. None of them address the current margin and same-store problem.

So Where's The Valuation Gap?

At a market cap of approximately $1.46 billion, Green Thumb trades at roughly 17 times trailing normalized EBITDA. The company is buying back shares at an average of $6.11, implying management sees value near current levels. Roth Capital recently lowered its price target from $20 to $18, while Seaport Research raised its to $18 from $17. Both targets suggest roughly 160% upside from current levels, which is an optimistic read on a business whose operating income fell 50% quarter-over-quarter.

The "priced too low" argument assumes that 280E relief, share buybacks, and eventual state-level growth will mechanically re-rate the stock. It doesn't account for the fact that gross margins have compressed by five points, same-store sales are negative, SG&A is accelerating, and management sees no sequential growth coming.

The Verdict: Hold, Not Buy

Green Thumb is not the bargain that the GAAP headline suggests. The operating business has weakened, and the tax relief driving the earnings headline is partial and incomplete. The company's competitive position — top market share in key states, a solid balance sheet, and aggressive buybacks — remains the best in the sector. But the margin deterioration and flat sequential guidance are real problems that the valuation hasn't started to reflect because everyone is focused on the GAAP flip-flop from loss to profit.

I wouldn't sell here. The balance sheet is strong, the buyback program provides a floor, and the 280E tailwind will continue to improve GAAP earnings even if operating metrics don't. But this isn't a moment to jump in.

I'd wait for three things before adding: a stabilization in gross margins below the current 45% trough, a return to positive same-store sales growth, and a quarterly revenue guide that shows sequential improvement rather than flatness. Until those signals appear, the operating story hasn't turned, and the "priced too low" case rests on a tax benefit that masks more than it reveals.